Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Palmer

Otolaryngology Philadelphia, PA Medical Doctor

NPI 1447287339 CMS profile 292178

3400 Spruce Street, 5 Silverstein Building, Philadelphia, PA 19104

Open in the dashboard

General payments

$331,377

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Palmer of Philadelphia, PA is reported in the CMS Open Payments database as having received $331,377 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,736 46
2024 General $55,560 53
2023 General $84,458 49
2022 General $1,892 25
2021 General $81,808 24
2020 General $1,262 6
2019 General $58,661 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Palmer
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to James Palmer were reported at $47,736. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year James Palmer Otolaryngology median Middle half National median
2019 $58,661 $194 $82–$512 $163
2020 $1,262 $118 $42–$280 $114
2021 $81,808 $167 $63–$444 $132
2022 $1,892 $216 $84–$545 $149
2023 $84,458 $235 $93–$588 $160
2024 $55,560 $280 $111–$699 $164
2025 $47,736 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. OptiNose US, Inc. $266,198 79 payments
  2. Medtronic, Inc. $40,932 51 payments
  3. Acclarent, Inc $16,285 36 payments
  4. Genzyme Corporation $1,945 6 payments
  5. Integra LifeSciences Corporation $1,601 14 payments
  6. 3-D Matrix, Inc. $1,524 3 payments
  7. Medtronic USA, Inc. $950 1 payment
  8. GlaxoSmithKline, LLC. $623 9 payments
  9. Regeneron Pharmaceuticals, Inc. $309 6 payments
  10. Aerin Medical Inc. $236 1 payment
  11. Other $775 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $302,914 28 payments
  2. Travel and Lodging $15,673 32 payments
  3. Food and Beverage $11,840 160 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $950 1 payment
Products named General payments · program years 2019–2025
  1. Xhance $266,198 79 payments
  2. PROPEL $15,270 17 payments
  3. STRAIGHTSHOT $13,963 13 payments
  4. TruDi NAV Cable $2,361 18 payments
  5. INSPIRA AIR $988 12 payments
  6. TruDi Probe $988 12 payments
  7. RELIEVA SPINPLUS NAV $988 12 payments
  8. ACCLARENT AERA $988 12 payments
  9. ACCLARENT Balloon Inflation Device $973 4 payments
  10. TruDi Nav Suction $973 4 payments
  11. Other $8,950 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

455

Median for Otolaryngology: 297

Drug cost

$28,171

Median for Otolaryngology: $6,314

Branded share of claims

25.7%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xhance Fluticasone Propionate Brand 38 $22,507
Ipratropium Bromide Generic 35 $1,278
Acetazolamide Er Acetazolamide Brand 13 $761
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 47 $590
Mupirocin Generic 34 $586
Montelukast Sodium Generic 26 $516
Prednisone Generic 105 $402
Levofloxacin Generic 42 $395
Omeprazole Generic 35 $373
Azithromycin Generic 21 $346

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$222,246

Medicare's payments for the services billed

Medicare patients

342

Average age 72

Services billed

1,344

177 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 50%
Ischemic heart disease 30%
Diabetes 27%
Depression 23%
Chronic kidney disease 18%
Cancer 18%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xhance
  • OptiNose US, Inc. $36,550
$36,550 38 —
DUPIXENT
  • GENZYME CORPORATION $281
  • Regeneron Pharmaceuticals, Inc. $224
  • Regeneron Healthcare Solutions, Inc. $19
$525 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record